2Kearney M T, CottonJm, Richardson P J, et al. Viral myocarditis and dilated cardiomyopathy: mechanism, manifestition and management[J]. Posigrad med, 2001, 77(903): 4-10.
3Feldman Am, mcnamara D. myocarditis[J]. Neng J Med, 2000, 343(19): 1388-1398.
4Liu P P, mason J W. Advances in the understanding of myocardites[J]. Circulation, 2001, 104: 1076-1082.
5Why H J F, Meany B T, Richardson P J, et al. Chinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiongpathy[J]. Circulation, 1994, 89(6): 2582.
6Chen R H, Bushell A, Fuggle S V, et al. Expression of granzyme A and perforin in mouse heart tranplants: immunosupressed with donor-specific tranfusion and anti-CD4 monoclonal antibosy[J]. Transplomtion, 1996, 61(4): 625-629.
4Hepler CD. Clinical pharmacy, pharmaceutical care, and the quality of drug therapy[J]. Pharmacotherapy,2004,24(11) :1491-1498.
5Hepler CD, Strand LM. Opportunities and responsibilities in phaima- ceutical care[J] .Am J Hosp Pharm,1990,47 (3) :533-543.
6Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowl- edge on aetiology, diagnosis, management, and therapy of myocardi- tis: a position statement of the European Society of Cardiology Work- ing Group on Myocardial and Peficardial Diseases [ J ]. Eur Heart J, 2013 ,34(33) :2636-2648.
